Andersen-Tawil syndrome secondary prevention: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Andersen-Tawil syndrome}} {{CMG}} ==Secondary Prevention== Prophylactic treatment aimed at reduction of attack frequency and severity can be achieved, as in other...") |
|||
| Line 5: | Line 5: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Prophylactic treatment aimed at reduction of attack frequency and severity can be achieved, as in other forms of periodic paralysis, with the following: | Prophylactic treatment aimed at reduction of attack frequency and severity can be achieved, as in other forms of periodic paralysis, with the following: | ||
* Lifestyle and dietary modifications to avoid known triggers | * Lifestyle and dietary modifications to avoid known triggers | ||
* Use of carbonic anhydrase inhibitors (acetazolamide 250-500 mg/1-2x/day or dichlorphenamide 50-100 mg/1-2x/day) | * Use of carbonic anhydrase inhibitors (acetazolamide 250-500 mg/1-2x/day or dichlorphenamide 50-100 mg/1-2x/day) | ||
* Daily use of slow-release potassium supplements, which may also be helpful in controlling attack rates in individuals prone to hypokalemia. Elevating the serum potassium concentration (>4 mEq/L) has the added benefit of narrowing the QT interval, thus reducing the risk of LQT-associated arrhythmias. | * Daily use of slow-release potassium supplements, which may also be helpful in controlling attack rates in individuals prone to hypokalemia. Elevating the serum potassium concentration (>4 mEq/L) has the added benefit of narrowing the QT interval, thus reducing the risk of LQT-associated arrhythmias. | ||
* An implantable cardioverter-defibrillator in individuals with tachycardia-induced syncope | * An implantable cardioverter-defibrillator in individuals with tachycardia-induced syncope | ||
* Empiric treatment with flecainide should be considered for significant, frequent ventricular arrhythmias in the setting of reduced left ventricular function. | * Empiric treatment with flecainide should be considered for significant, frequent ventricular arrhythmias in the setting of reduced left ventricular function. | ||
Revision as of 21:33, 24 February 2013
|
Andersen-Tawil syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Andersen-Tawil syndrome secondary prevention On the Web |
|
American Roentgen Ray Society Images of Andersen-Tawil syndrome secondary prevention |
|
Risk calculators and risk factors for Andersen-Tawil syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Secondary Prevention
Prophylactic treatment aimed at reduction of attack frequency and severity can be achieved, as in other forms of periodic paralysis, with the following:
- Lifestyle and dietary modifications to avoid known triggers
- Use of carbonic anhydrase inhibitors (acetazolamide 250-500 mg/1-2x/day or dichlorphenamide 50-100 mg/1-2x/day)
- Daily use of slow-release potassium supplements, which may also be helpful in controlling attack rates in individuals prone to hypokalemia. Elevating the serum potassium concentration (>4 mEq/L) has the added benefit of narrowing the QT interval, thus reducing the risk of LQT-associated arrhythmias.
- An implantable cardioverter-defibrillator in individuals with tachycardia-induced syncope
- Empiric treatment with flecainide should be considered for significant, frequent ventricular arrhythmias in the setting of reduced left ventricular function.